tbuckley/cabot-search huggingface dataset:
Diabetes and Cardiovascular Disease Outcomes in the Metabolically Healthy Obese Phenotype
Authors: Sarah L. Appleton, Christopher J. Seaborn, Renuka Visvanathan, Catherine L. Hill, Tiffany K. Gill, Anne W. Taylor, Robert J. Adams
Journal: Diabetes Care (2013)

To determine the correlates of the "metabolically healthy obese" (MHO) phenotype and the longitudinal risks of diabetes and cardiovascular disease (CVD)/stroke associated with this phenotype.The North West Adelaide Health Study is a prospective cohort study of 4,056 randomly selected adults aged ≥ 18 years. Participants free of CVD/stroke and not underweight (n = 3,743) were stratified by BMI categories and metabolic risk, defined as having two or more International Diabetes Federation metabolic syndrome criteria, excluding waist circumference.Correlates of the MHO (n = 454 [12.1%]) included smoking, socioeconomic disadvantage, and physical inactivity. Compared with metabolically healthy normal-weight subjects (n = 1,172 [31.3%]), the MHO were more likely to develop metabolic risk (15.5 vs. 33.1%, P < 0.001) and incident diabetes (odds ratio 2.09 [95% CI 0.87-5.03]) but not CVD/stroke (1.16 [0.58-2.29]) during 5.5-10.3 years of follow-up. These risks were not seen in MHO subjects maintaining metabolic health (n = 188 [67%]). Sustained metabolic health in obese participants was associated with age ≤ 40 years and lower waist circumference. Compared with the metabolically at-risk obese, MHO women demonstrated a significantly higher (mean [SE]) percentage of leg fat (49.9 [0.5] vs. 53.2 [0.7]) and lower waist circumference (104 [0.6] vs. 101 cm [0.8]), despite no significant differences in overall adiposity."Healthy" obesity was a transient state for one-third of subjects. Persistence of a MHO phenotype, which was associated with favorable outcomes, was related to younger age and a more peripheral fat distribution. The MHO phenotype may be sustained by promoting lower waist circumferences.
EFFECTS OF α-KETOISOCAPROATE AND OF LEUCINE ON NITROGEN METABOLISM IN POSTOPERATIVE PATIENTS
Authors: DanielG. Sapir, Mackenzie Walser, ElizabethD. Moyer, NeilB. Rosenshein, PeterM. Stewart, Connie Moreadith, AnthonyL. Imbembo, Santiago Munoz
Journal: The Lancet (1983)
Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure
Authors: Valerio Zacà, Sharad Rastogi, Makoto Imai, Mengjun Wang, Victor G. Sharov, Alice Jiang, Sidney Goldstein, Hani N. Sabbah
Journal: Journal of the American College of Cardiology (2007)
Effect of Ascorbic Acid on Endurance Performance and Athletic Injury
Authors: George O. Gey
Journal: JAMA (1970)

It has been postulated that supplemental doses of ascorbic acid (vitamin C) may improve endurance performance and perhaps reduce the severity and morbidity of athletic injuries.<sup>1-4</sup>The present study was designed to answer these questions and to determine the long-term effects of a large supplemental dose of ascorbic acid in contrast to those of a placebo. <h3>Materials and Methods</h3> Two hundred and eighty-six male officers (average age, 28.0 years) participated in this study while attending the 12-week Squadron Officers School, Maxwell Air Force Base, Ala. Each officer ran the 12-minute field test<sup>5</sup>at the beginning of training and then was given a bottle containing either 500-mg tablets of ascorbic acid or a placebo. The bottles were numbered at random with a code that was kept in strict secrecy until completion of the study. The subjects were instructed to take two pills each day throughout the training period. Also,
Elicitation of the prausnitz-kustner reaction by antiidiotypic antibodies.
Authors: R S Geha
Journal: Journal of Clinical Investigation (1982)

Rabbit antiidiotypic IgG directed against IgG F(ab')2 anti-tetanus toxoid (TT) antibodies ("idiotype") elicited a Prausnitz-Kustner reaction in normal skin sites sensitized 48 h earlier with the serum of the idiotype donor that contained IgE anti-TT antibodies. The serum moiety that caused the sensitization was heat sensitive (56 degrees C, 1 h), and was specifically removed by passage over immunosorbents containing rabbit antihuman IgE or TT antigen. The data obtained indicate that human IgG and IgE antibodies share idiotypic determinants and raise the possibility that idiotypic interactions may play a role in the regulation of the IgE antibody response in man.
NITINOL STENTING FOR CHRONIC TOTAL OCCLUSION (CTO) IN SUPERFICIAL FEMORAL ARTERY (SFA), LONG-TERM CLINICAL OUTCOMES FROM MULTICENTER REGISTRY.
Authors: Yasunari Sakamoto, Keisuke Hirano, Toshiya Muramatsu, Yoshimitsu Soga, Osamu Iida, Yokoi Hiroyoshi, Shinsuke Nanto
Journal: Journal of the American College of Cardiology (2010)
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?
Authors: A T Cohen, J A Skinner, V V Kakkar
Journal: BMJ (1994)

A recent meta-analysis from the Antiplatelet Trialists' Collaboration recommended that anti- latelet treatment either alone or, for greater effect, in addition to other proved forms of thromboprophy- laxis should be considered for patients at high risk of thromboembolism.This paper argues that the current evidence does not justify the adoption of aspirin or other antplatelet treatment for venous thromboprophylaxis, especially when more effective alternatives exist.Furthermore, several issues relating to this latest meta-analysis need to be debated.
The Candy Store
Authors: Robert P. Hudson
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
18F-FDG PET/CT Imaging of Sister Mary Joseph's Nodule
Authors: Denis Métivier, Gérald Bonardel, Delphine Rouquie, Eric Gontier, Cyrus Chargari, Céline Dechaud, Hervé Foehrenbach, Olivier Chapuis
Journal: Clinical Nuclear Medicine (2012)

An 82-year-old woman was followed up for an uterine cervical adenocarcinoma treated by surgery. A whole-body fluorodeoxyglucose positron emission tomography study revealed a pathologic fluorodeoxyglucose uptake located in the umbilicus associated to peritoneal carcinomatosis. Biopsy of the umbilical nodule demonstrated an umbilical metastasis from the uterine adenocarcinoma, the so-called "Sister Mary Joseph's nodule."
Geometric features of coronary artery lesions favoring acute occlusion and myocardial infarction: a quantitative angiographic study
Authors: Francois Ledru, Pierre Théroux, Jacques Lespérance, Jean Laurier, Pierre Ducimetière, Jean-Léon Guermonprez, Benoit Diébold, Didier Blanchard
Journal: Journal of the American College of Cardiology (1999)
Transgenic expression of cholesterol 7α-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice
Authors: Tiangang Li, Erika Owsley, Michelle Matozel, Peter Hsu, Colleen M. Novak, John Y. L. Chiang
Journal: Hepatology (2010)

Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme in the bile acid biosynthetic pathway that converts cholesterol into bile acids in the liver. Recent studies have shown that bile acids may play an important role in maintaining lipid, glucose, and energy homeostasis. However, the role of CYP7A1 in the development of obesity and diabetes is currently unclear. In this study, we demonstrated that transgenic mice overexpressing Cyp7a1 in the liver [i.e., Cyp7a1 transgenic (Cyp7a1-tg) mice] were resistant to high-fat diet (HFD)–induced obesity, fatty liver, and insulin resistance. Cyp7a1-tg mice showed increased hepatic cholesterol catabolism and an increased bile acid pool. Cyp7a1-tg mice had increased secretion of hepatic very low density lipoprotein but maintained plasma triglyceride homeostasis. Gene expression analysis showed that the hepatic messenger RNA expression levels of several critical lipogenic and gluconeogenic genes were significantly decreased in HFD-fed Cyp7a1-tg mice. HFD-fed Cyp7a1-tg mice had increased whole body energy expenditure and induction of fatty acid oxidation genes in the brown adipose tissue. Conclusion: This study shows that Cyp7a1 plays a critical role in maintaining whole body lipid, glucose, and energy homeostasis. The induction of CYP7A1 expression with the expansion of the hydrophobic bile acid pool may be a potential therapeutic strategy for treating metabolic disorders such as fatty liver diseases, obesity, and diabetes in humans. (HEPATOLOGY 2010;)
Bromocriptine in Parkinsonism
Authors: D. B. Calne, P. F. Teychenne, L. E. Claveria, R. Eastman, J. K. Greenacre, A. Petrie
Journal: BMJ (1974)

Bromocriptine, a drug acting directly upon dopaminergic receptors, has been found to have a significant therapeutic action in a double-blind study of 20 patients with idiopathic Parkinsonism who were already receiving conventional therapy, including levodopa. Neurological deficits improved by almost 20% in severely disabled patients; amelioration of mildly affected patients was about 10%. Adverse reactions were similar to those encountered with levodopa—they were all dose-dependent and reversible. These observations are discussed in relation to certain theoretical advantages which might be expected from a drug which acts directly on dopaminergic receptors.
Beef Sheds Fat For Better Fit With Diet Guidelines
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Beef Sheds Fat For Better Fit With Diet Guidelines Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 18, 19 September 1990, Pages 1454–1455, https://doi.org/10.1093/jnci/82.18.1454 Published: 19 September 1990
Carcinoma of the Colon and Rectum
Authors: C. K. McSherry, G. N. Cornell, F. Glenn
Journal: CA A Cancer Journal for Clinicians (1969)

little evidence of further improvement of survival based on the experience re ported herein.There were 121 patients who had re sections of adjacent structures in the course of curative operations.Fifty three consisted of segments of small bowel; forty-four women had part or all their reproductive organs removed.Partial cystectomies were performed in 17 and total cystectomies in seven.
Exercise-Induced Abdominal Pain-Reply
Authors: George E. Block
Journal: JAMA (1983)

In Reply.—  It is conceivable that in some slender, asthenic persons, extreme mobility of a kidney may occasionally cause discomfort with vigorous physical activity. Symptomatic relief by abdominal binders is not necessarily indicative that this renal mobility is the genesis of the symptoms described.  Even if the association is occasionally valid, the mobility of a kidney should not be used as an indication for nephropexy—an operation that formerly enjoyed great popularity, proved to be worthless, and has been rightfully abandoned.
We Can Change the Natural History of Type 2 Diabetes
Authors: Lawrence S. Phillips, Robert E. Ratner, John B. Buse, Steven E. Kahn
Journal: Diabetes Care (2014)

As diabetes develops, we currently waste the first ∼10 years of the natural history. If we found prediabetes and early diabetes when they first presented and treated them more effectively, we could prevent or delay the progression of hyperglycemia and the development of complications. Evidence for this comes from trials where lifestyle change and/or glucose-lowering medications decreased progression from prediabetes to diabetes. After withdrawal of these interventions, there was no "catch-up"-cumulative development of diabetes in the previously treated groups remained less than in control subjects. Moreover, achieving normal glucose levels even transiently during the trials was associated with a substantial reduction in subsequent development of diabetes. These findings indicate that we can change the natural history through routine screening to find prediabetes and early diabetes, combined with management aimed to keep glucose levels as close to normal as possible, without hypoglycemia. We should also test the hypothesis with a randomized controlled trial.
Clinical trials update from the American Heart Association meeting: ACORN‐CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A‐HeFT, GEMINI, vitamin E meta‐analysis, ESCAPE, CARP, and SCD‐HeFT cost‐effectiveness study
Authors: Rhidian J. Shelton, Periaswamy Velavan, Nikolay P. Nikitin, Alison P. Coletta, Andrew L. Clark, Alan S. Rigby, Nick Freemantle, John G.F. Cleland
Journal: European Journal of Heart Failure (2004)
Lipid droplet-associated proteins in high-fat fed mice with the effects of voluntary running and diet change
Authors: Rita Rinnankoski-Tuikka, Juha J. Hulmi, Sira Torvinen, Mika Silvennoinen, Maarit Lehti, Riikka Kivelä, Hilkka Reunanen, Urho M. Kujala, Heikki Kainulainen
Journal: Metabolism (2014)
Copper-metallothioneins in the American lobster, Homarus americanus: potential role as Cu(I) donors to apohemocyanin.
Authors: M Brouwer, P Whaling, D W Engel
Journal: Environmental Health Perspectives (1986)

The physiological function of copper(I)-metallothionein is not well understood. The respiratory function of hemocyanin, a copper(I)-containing respiratory protein found in the hemolymph of many invertebrates, has been known a long time. However, the mechanism by which Cu(I) is inserted into the oxygen-binding site of apohemocyanin is completely unknown. This investigation tests the hypothesis that copper(I)-metallothionein may act as a Cu(I) donor to apohemocyanin. To this end, copper-binding proteins and hemocyanin were purified from the digestive gland and hemolymph of the American lobster, Homarus americanus. In the presence of beta-mercaptoethanol, the copper-binding proteins can be resolved into three components on DEAE-cellulose. The first two have been characterized as metallothioneins, based on their high cysteine content and lack of aromatic amino acid residues. The cysteine content of the third component is half of that of components I and II. In the absence of beta-mercaptoethanol the three proteins elute as a single protein complex during ion-exchange chromatography. Components I and II show a strong tendency to polymerize, a process that is accompanied by the loss of protein-bound copper. The purified proteins are not capable of transferring Cu(I) to the active sites of completely copper-free apohemocyanin. They are capable, however, of transferring Cu(I) to active sites of hemocyanin containing reduced amounts of Cu(I), suggesting that the conformational state of hemocyanin is the determining factor in the Cu(I) transfer mechanism.
Legislating against Use of Cost-Effectiveness Information
Authors: Peter J. Neumann, Milton C. Weinstein
Journal: New England Journal of Medicine (2010)

The Patient-Centered Outcomes Research Institute . . . shall not develop or employ a dollars per quality adjusted life year (or similar measure that discounts the value of a life because of an individual's disability) as a threshold to establish what type of health care is cost effective or recommended. The Secretary shall not utilize such an adjusted life year (or such a similar measure) as a threshold to determine coverage, reimbursement, or incentive programs under title XVIII.— The Patient Protection and Affordable Care Act1 In 1996, after 2 years of deliberation, the U.S. Panel on Cost-Effectiveness in Health and Medicine, . . .
Reports of DHPG Treatment of Cytomegalovirus Retinitis
Authors: KEITH HENRY
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 July 1986Reports of DHPG Treatment of Cytomegalovirus RetinitisKEITH HENRY, M.D.KEITH HENRY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-1-144_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: In theAnnals'January issue, Masur and colleagues (1) reported on the effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) on serious cytomegalovirus disease in 8 immunosuppressed homosexual men. The data outlined in that article bear some resemblance to data included in their paper published in the January issue of the American Journal of Ophthalmology (2). I was unable to tell whether these papers included data on some of the same patients or whether they represented two entirely different studies on separate patient groups. If these articles do represent different studies, then the amount of information regarding the authors' use...References1. MASURLANEPALESTINE HHA. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med. 1986;104:41-4. LinkGoogle Scholar2. PALESTINESTEVENSLANE AGH. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986;101:95-101. CrossrefMedlineGoogle Scholar1. MASURLANEPALESTINE HHA. EfTect of 9-(1,3-dyhydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Ann Intern Med. 1986;104:41-4. LinkGoogle Scholar2. PALESTINESTEVENSLANE AGH. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986:101:95-101. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Minnesota Medical School St. Paul-Ramsey Medical Center St. Paul, MN 55101 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAccurate Case Counts: The Problem and a ProposalELIAS ABRUTYN, M.D. 1 July 1986Volume 105, Issue 1Page: 144-145KeywordsHomosexualsOphthalmologyRetinitis Issue Published: 1 July 1986 PDF downloadLoading ...
Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism
Authors: N. Desai, S. Heenan, P.S. Mortimer
Journal: British Journal of Dermatology (2009)

Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is increasingly used as an agent for post-transplant immunosuppression and the treatment of solid organ and haematological malignancies and hamartomas. Its advantages include a lack of nephrotoxicity and a lower incidence of nonmelanoma skin cancers; adverse effects include delayed wound healing, increased lymphocoele formation and rarely lymphoedema. We report a series of eight cases of severe, sustained, unilateral and bilateral lymphoedema in patients receiving sirolimus for post-transplant immunosuppression, classify their lymphoscintigraphy findings and propose a mechanism of aetiology based on the interaction of mTOR with key mediators of lymphangiogenesis.
The use and abuse of Distalgesic.
Authors: J Farrell, A W Brown, R D Sturrock
Journal: BMJ (1979)

brought to hospital having been found unconscious at home after sniffing Evostik glue.Almost immediately on arrival at hospital he had a typical grand mal convulsion, which was controlled by 5 mg of diazepam given intravenously.He regained consciousness after 20 minutes and was detained in hospital for four days.Investigations revealed no evidence of hepatic or renal dysfunction and he was subsequently discharged home.It is not known whether this patient had indulged in glue sniffing in the past.
Omalizumab Pretreatment Does Not Protect Against Peanut Oral Immunotherapy-Related Adverse Gastrointestinal Events
Authors: Uyenphuong Le, Yamini Virkud, Brian P. Vickery, Pamela H. Steele, Janet S. Kamilaris, Michael D. Kulis, Jelena Berglund, A. Wesley Burks
Journal: Journal of Allergy and Clinical Immunology (2014)
Global health goals depend not just on more aid but better delivery
Authors: Peter Moszynski
Journal: BMJ (2008)

<h3>Abstract</h3> Species-specific differentiation pace in in vitro assays indicates that some aspects of neural differentiation are driven by cell-autonomous processes. Here we describe a novel in vitro human neural rosette assay that recapitulates the temporal sequence of dorsal spinal cord differentiation but proceeds more rapidly than in the human embryonic spinal cord, suggesting that in vitro conditions lack endogenous signalling dynamics. To test the extent to which this in vitro assay represents a cell intrinsic differentiation programme, human iPSC-derived neural rosettes were homo-chronically grafted into the faster differentiating chicken embryonic neural tube. Strikingly, in vitro human differentiation pace was not accelerated, even in single host-integrated cells. Moreover, rosette differentiation eventually stalled in a neural progenitor cell state. These findings demonstrate the requirement for timely extrinsic signalling to accurately recapitulate human neural differentiation tempo, and suggest that while intrinsic properties limit differentiation pace, such signals are also required to maintain differentiation progression.
FOLLICULITIS ULERYTHEMATOSA RETICULATA: WITH A REPORT OF A CASE
Authors: NORMAN BURGESS
Journal: British Journal of Dermatology (1932)

Journal Article FOLLICULITIS ULERYTHEMATOSA RETICULATA: WITH A REPORT OF A CASE Get access NORMAN BURGESS, M.A., M.D.CAMB., M.R.C.P.Lond. NORMAN BURGESS, M.A., M.D.CAMB., M.R.C.P.Lond. Assistant Physician, Skin Department, Bristol General Hospital Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 44, Issue 7, 1 July 1932, Pages 357–367, https://doi.org/10.1111/j.1365-2133.1932.tb09616.x Published: 01 July 1932
Plasma Fibrinogen Patterns in Patients with Coronary Atherosclerosis
Authors: JAMES W. HAMPTON, JAMES MANTOOTH, EDWARD N. BRANDT, STEWART G. WOLF
Journal: Circulation (1966)

Plasma fibrinogen determinations in 46 coronary patients and 49 healthy individuals were made over a period of about 33 months. The mean fibrinogen levels were calculated and shown to increase with age. The fibrinogen levels in the younger patient group were elevated and resembled the levels of the older control subjects. The statistical test of the variance was significantly greater in the patient group. The inclusion of episodes of infections, bleeding, and surgery, all of which are known to raise the plasma fibrinogen levels, did not significantly alter the greater fibrinogen variance in the patient group. Comparison of a group of patients receiving anticoagulant orally to a group not receiving the drugs failed to indicate that the anticoagulants restored the lower variance seen in the controls. Of the four patients whose deaths were documented as due to recurrent coronary events, all had greater fibrinogen variances than a comparable group of patients who survived. The fibrinogen variance may not only reflect an unstable clotting mechanism in patients with coronary thrombosis but may also have prognostic significance for the recurrence of myocardial infarction.